BCD-225
/ Biocad
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 17, 2026
Antitumor activity of BCD-225, an IL-15 receptor superagonist, in syngeneic tumor models: dose-dependent efficacy in monotherapy and combination with anti-PD-1
(ESMO 2026)
- No abstract available
Monotherapy • Preclinical • Oncology • IL15
1 to 1
Of
1
Go to page
1